Sponsored

Cynata (ASX:CYP) receives ~AU$1.65 million R&D Tax Incentive Refund

December 05, 2022 04:32 AM GMT | By Manisha
 Cynata (ASX:CYP) receives ~AU$1.65 million R&D Tax Incentive Refund
Image source: © Gajus | Megapixl.com

Highlights

  • Cynata Therapeutics Limited has been granted a AU$1,654,310 R&D Tax Incentive Refund for FY21/22.
  • The refund strengthens Cynata’s healthy balance sheet, which stood at around AU$18.3 million cash at the end of the September quarter.
  • Cynata plans to utilise the funds to advance its diverse and advanced cell therapy product pipeline.

In the latest announcement, clinical-stage biotechnology company Cynata Therapeutics (ASX:CYP) revealed that it has received an R&D Tax Incentive Refund of AU$1.65 million for the financial year 2021/2022. The grant further strengthens Cynata’s cash position which was AU$18.3 million at the end of the September quarter.

Cynata Therapeutics is an Australian clinical-stage stem cell and regenerative medicine firm engaged in the development of therapies based on its unique and proprietary therapeutic stem cell platform technology, Cymerus™.

Cymerus™ makes use of Nobel prize winning iPSC (induced pluripotent stem cells) technology to produce mesenchymal stem cells (MSCs) from single donor and a single donation, to enable highly consistent MSC product manufacture at commercial scale.

Utilising the proceeds

According to the company announcement, Cynata will direct the funds obtained from The Tax Incentive Refund to build further resources that can contribute towards advancing its diverse and innovative cell therapy product pipeline. The Company currently has ongoing clinical trials in osteoarthritis and diabetic foot ulcers, with plans to soon commence clinical trials in in acute graft-versus-host disease (aGvHD) and renal transplantation.

About R&D Tax Incentive

The R&D Tax Incentive is one of the vital Australian Government programs that plays a significant role in encouraging firms to undertake research and development works that are progressive for the country.

Under the program, a tax offset is offered to the companies for eligible activities, including Cynata’s efforts for developing its proprietary Cymerus™ therapeutic mesenchymal stem cell (MSC) products.

Shares of Cynata were trading at AU$0.330 apiece on Monday (05 December 2022).


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Limited, Company No. 12643132 (Kalkine Media, we or us) and is available for personal and non-commercial use only. Kalkine Media is an appointed representative of Kalkine Limited, who is authorized and regulated by the FCA (FRN: 579414). The non-personalised advice given by Kalkine Media through its Content does not in any way endorse or recommend individuals, investment products or services suitable for your personal financial situation. You should discuss your portfolios and the risk tolerance level appropriate for your personal financial situation, with a qualified financial planner and/or adviser. No liability is accepted by Kalkine Media or Kalkine Limited and/or any of its employees/officers, for any investment loss, or any other loss or detriment experienced by you for any investment decision, whether consequent to, or in any way related to this Content, the provision of which is a regulated activity. Kalkine Media does not intend to exclude any liability which is not permitted to be excluded under applicable law or regulation. Some of the Content on this website may be sponsored/non-sponsored, as applicable. However, on the date of publication of any such Content, none of the employees and/or associates of Kalkine Media hold positions in any of the stocks covered by Kalkine Media through its Content. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music/video that may be used in the Content are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music or video used in the Content unless stated otherwise. The images/music/video that may be used in the Content are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

AI on the Rise: A Look at Top AI Companies and Their Stocks

Sponsored Articles


Investing Ideas

Previous Next